Is cyproheptadine used off‑label for drug‑induced sexual dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cyproheptadine for Drug-Induced Sexual Dysfunction

Yes, cyproheptadine is used off-label for drug-induced sexual dysfunction, particularly for serotonin reuptake inhibitor (SRI)-induced anorgasmia and delayed orgasm, though evidence for its efficacy is limited and conflicting.

Evidence Base and Clinical Context

The use of cyproheptadine for this indication stems from its mechanism as a 5-HT2 serotonin receptor antagonist, which theoretically counteracts the excessive serotonergic activity that causes sexual dysfunction with SSRIs and other serotonergic antidepressants 1, 2.

Supporting Evidence

Several case series and retrospective studies document cyproheptadine's use for SRI-induced sexual dysfunction:

  • A large retrospective study of 596 psychiatric outpatients found that among 97 patients (16.3%) who developed SRI-induced sexual dysfunction, 45 tried antidote therapy. Cyproheptadine was one of three agents tested (along with yohimbine and amantadine), but yohimbine was significantly more effective than cyproheptadine in reversing sexual dysfunction 1.

  • Smaller case series (7 patients) showed that 5 of 7 men with SRI-induced decreased libido and anorgasmia improved with cyproheptadine 4-12 mg taken 1-2 hours before sexual activity, though improvement was transitory in 2 patients. All experienced sedation the following day 2.

  • Individual case reports document successful reversal of anorgasmia induced by fluoxetine and citalopram with cyproheptadine 3, 4.

Critical Limitations

The evidence quality is poor: no randomized controlled trials exist, only case reports and small case series. A 2012 systematic review examining strategies for antipsychotic-induced sexual dysfunction found that cyproheptadine did not improve sexual function in randomized controlled studies 5.

Practical Clinical Algorithm

When to Consider Cyproheptadine

  1. Primary indication: SRI-induced anorgasmia or delayed orgasm that persists despite adequate trial duration
  2. After first-line strategies fail:
    • Dose reduction of the offending agent (if psychiatrically stable)
    • Switching to bupropion or mirtazapine (which have lower sexual dysfunction rates) 6
    • Trial of sildenafil for erectile dysfunction component 5

Dosing Strategy

  • 4-12 mg taken 1-2 hours before anticipated sexual activity (not daily dosing) 2
  • Start at 4 mg and titrate based on response
  • This "as-needed" approach minimizes systemic side effects

Expected Outcomes and Pitfalls

Common pitfall: Sedation occurs universally and persists into the next day, which significantly impacts tolerability 2. Patients must be warned about this before the first dose.

Realistic expectations: Even when "successful," improvement may be partial or transitory. The response rate appears lower than with yohimbine or switching strategies 1.

Contraindications per FDA labeling: Newborns, premature infants, nursing mothers, patients on MAO inhibitors, and those with angle-closure glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction 7.

Caution required: History of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypertension due to atropine-like effects 7.

Alternative Approaches with Stronger Evidence

Given cyproheptadine's limited and conflicting evidence, prioritize these alternatives first:

  1. Switch to bupropion: Significantly lower rates of sexual dysfunction than fluoxetine or sertraline 6
  2. Add sildenafil or other PDE5 inhibitors: Demonstrated efficacy in randomized trials for antipsychotic-induced sexual dysfunction 5
  3. Switch to aripiprazole (for antipsychotic-induced dysfunction): Shown effective in randomized controlled trials 5

Bottom Line

Cyproheptadine represents a third-line or later option for SRI-induced sexual dysfunction, specifically anorgasmia, when switching antidepressants or using PDE5 inhibitors is not feasible. The evidence supporting its use consists entirely of case reports and small case series, with one large retrospective study showing it was less effective than yohimbine 1. Universal next-day sedation significantly limits its practical utility. Consider it only after exhausting better-evidenced strategies, and counsel patients extensively about the high likelihood of sedation and uncertain benefit.

References

Related Questions

What is the recommended approach to manage sexual dysfunction in a patient taking temazepam (a benzodiazepine) for insomnia?
How should decreased libido caused by sertraline be treated?
What are the treatment options for anorgasmia in males taking Selective Serotonin Reuptake Inhibitors (SSRIs)?
What is the likely differential diagnosis for a male patient with decreased libido, fatigue, social withdrawal, insomnia, and recent onset of decreased sexual interest, who takes sleeping pills and prefers solitude?
Can antidepressant treatment cause anorgasmia as an adverse effect?
Can a Psychiatric-Mental Health Nurse Practitioner (PMHNP) prescribe oral iron for an adult with iron deficiency, and what is the recommended elemental iron dosage?
What is the normal range for aspartate aminotransferase (AST) and how are different levels of elevation interpreted?
What causes brief cyanotic episodes of the hands, feet, lips, and face, and what is the appropriate evaluation and management?
Can cutaneous human papillomavirus (HPV) that causes common skin warts affect the external skin of the genital area (e.g., mons pubis) away from the mucosal surfaces?
What are the anatomical landmarks for sacroiliac joint injection?
What hospital isolation precautions are recommended for a patient with disseminated herpes infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.